Literature DB >> 8032219

Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3.

M Mottolese1, I Venturo, M Benevolo, F Di Filippo, M Lopez, A Bigotti, P G Natali.   

Abstract

The analysis of fine-needle aspirates and effusions has proved to be a valuable tool for the cytological identification of metastatic melanoma. Nevertheless, while malignant pigmented cells can be easily detected on cytological specimens, their identification may be very difficult in patients bearing amelanotic lesions. In the present study we have evaluated whether this limitation can be overcome using two monoclonal antibodies (mAbs) HMB45 and Ep1-3, which are highly specific for the melanocyte lineage. These reagents were assayed in immunocytochemical tests performed on cytological material obtained from 50 patients with a past history of melanoma and 463 bearing metastases from a cryptic primary tumour. These mAbs, employed in combination with a panel of monoclonal reagents with well-defined tumour specificity, may improve the accuracy of the conventional cytopathological diagnosis of melanoma metastases in the two groups of patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032219     DOI: 10.1097/00008390-199402000-00008

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  3 in total

Review 1.  [Secondary malignant melanoma of the gallbladder. A contribution to the differential diagnosis of pigmented lesions of the gallbladder].

Authors:  N Gassler; N Banafsche; A Quentmeier; H F Otto; B M Helmke
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

2.  Melanocyte progenitor cells reside in human subcutaneous adipose tissue.

Authors:  Yuri Ikeda; Akino Wada; Toshio Hasegawa; Mutsumi Yokota; Masato Koike; Shigaku Ikeda
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

3.  Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.

Authors:  M Mottolese; I Venturo; M Rinaldi; M Lopez; G Bigotti; M Benevolo; P G Natali
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.